SCHEMBL3129685

SCHEMBL3129685

O=C(NCc1ccc(C(F)(F)F)c(Cl)c1)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 9/20 0.77
SCN9A Q15858 2/20 0.60
SCN1A P35498 1/20 0.60
KCNH2 Q12809 1/20 0.60
SCN5A Q14524 1/20 0.60
SCN2A Q99250 1/20 0.60
SCN8A Q9UQD0 1/20 0.60
SCN10A Q9Y5Y9 1/20 0.60
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
NAMPT P43490 1/20 0.48
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
AVPR2 P30518 1/20 0.48
GPR27 Q9NS67 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3160268 0.93 SCN3A (0.75) SCN3ASCN9ASCN1AKCNH2SCN5A
SCHEMBL13448359 0.90 SCN3A (0.70) SCN3ASCN9ASCN1AKCNH2SCN5A
SCHEMBL3159795 0.90 SCN3A (0.76) SCN3ASCN9ASCN1AKCNH2SCN5A
SCHEMBL3168747 0.89 SCN3A (0.62) SCN3ASCN9ASCN1AKCNH2SCN5A
SCHEMBL3165684 0.89 SCN3A (0.75) SCN3ASCN9ASCN1AKCNH2SCN5A
SCHEMBL3163272 0.88 SCN3A (0.75) SCN3ASCN9ASCN1AKCNH2SCN5A
SCHEMBL3130817 0.88 SCN3A (0.60) SCN3ASCN9ASCN1AKCNH2SCN5A
SCHEMBL3124501 0.88 SCN3A (0.78) SCN3ASCN9ASCN1AKCNH2SCN5A
SCHEMBL13448356 0.87 SCN3A (0.66) SCN3ASCN9ASCN1AKCNH2SCN5A
SCHEMBL3125226 0.87 SCN3A (1.00) SCN3ASCN9ASCN1AKCNH2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
WO-2010035166-A1 BENZAMIDE DERIVATIVES PFIZER LIMITED (GB) 2010-04-01 WO disclosed
WO-2010035166-A1 BENZAMIDE DERIVATIVES PFIZER LIMITED (GB) 2010-04-01 WO disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN9A 51/4885SCN1A 6/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN9A 51/4885SCN1A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.